Among the trials presented at the AASLD meeting was a study of telaprevir, a protease inhibitor that is currently in Phase III trials (Table 1). Patients infected with HCV genotype 1 who had ...

The hepatitis C virus (HCV) is believed to have infected approximately 170 million people worldwide (Fig. 1). Often referred to as the silent killer, patients can remain asymptomatic for decades ...

hepatitis C virus; mRNA, messenger RNA; PI, protease inhibitor; NS, nonstructural protein; RdRp, RNA-dependent RNA polymerase; —, no drugs in this class in this phase of development.

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...

Direct-acting antivirals (DAAs) target different steps of hepatitis C reproduction. These include hepatitis C protease inhibitors, polymerase inhibitors and NS5A inhibitors. Recommended regimens ...

Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful ...

but no prior treatment with an HCV NS3/4A protease inhibitor or NS5A inhibitor; (genotype 3): treat for 16 weeks if previously treated with regimens containing PEG-IFN, ribavirin, and/or ...

In their review article the authors present the results from the licensing studies for two recently approved hepatitis C virus (HCV) protease inhibitors (boceprevir, telaprevir). Both substances ...

Are you searching for medications to treat 'Hepatitis C'? Welcome to this page which serves as an archive for medications that are relevant to the treatment of Hepatitis C. The page includes both ...

May be potentiated by atorvastatin, acetaminophen, ascorbic acid, or CYP3A4 inhibitors (eg, itraconazole, ketoconazole). May be affected by HIV/HCV protease inhibitors, NNRTIs. May antagonize ...

Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

hepatitis C virus; mRNA, messenger RNA; PI, protease inhibitor; NS, nonstructural protein; RdRp, RNA-dependent RNA polymerase; —, no drugs in this class in this phase of development.